Cathie Wood’s ARK Funds Snapped Up Crispr Shares Ahead of Plunge_老虎社区_美港股上老虎

Cathie Wood’s ARK Funds Snapped Up Crispr Shares Ahead of Plunge

Bloomberg2021-10-13

(Bloomberg) -- Crispr Therapeutics AG plunged 8.8% in postmarket trading Tuesday after an experimental blood cancer therapy disappointed investors. That may spell more bad news for a Cathie Wood fund ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

Ares_M
·2021-10-13
Anybody with some knowledge in Genetic engineering would take this as a chance to buy the dip, CRSP is only going one way on the long term: up
回复
点赞
举报
raidou
·2021-10-13
Woooo
回复
2
举报
收起
- raidou:
  [龇牙] [微笑] [龇牙] [惊讶] [微笑] [惊讶] [笑哭] [惊讶] [笑哭] [惊讶] [笑哭] [惊讶] [惊讶] [笑哭] [生气] [微笑] [生气] [微笑] [生气] [微笑] [生气] [生气] [微笑]
  2021-10-13
  回复
  举报
- raidou:
  [龇牙] [微笑] [龇牙] [微笑] [惊讶] [开心] [惊讶] [惊讶] [开心] [惊讶] [开心] [惊讶] [开心] [惊讶] [难过] [惊讶] [难过] [惊讶] [惊讶] [难过] [惊讶] [开心] [害羞] [开心] [开心]
  2021-10-13
  回复
  举报
- raidou:
  [流泪] [笑哭] [害羞] [笑哭] [害羞] [笑哭] [害羞] [害羞] [笑哭] [害羞] [笑哭] [害羞] [笑哭] [害羞] [笑哭] [害羞] [笑哭] [真香] [笑哭] [笑哭]
  2021-10-13
  回复
  举报
查看更多 2 条评论
Nebhol
·2021-10-13
Good
回复
点赞
举报
HermioneG
·2021-10-13
Awesome!
回复
1
举报
收起
- Cylee3325:
  Great
  2021-10-13
  回复
  举报
- RS142:
  good
  2021-10-13
  回复
  举报

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1113160181?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-10-13 08:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1113160181","market":"us","top_or_hot":-1,"title":"Cathie Wood’s ARK Funds Snapped Up Crispr Shares Ahead of Plunge","media":"Bloomberg","content":"<div>\n<p>(Bloomberg) -- Crispr Therapeutics AG plunged 8.8% in postmarket trading Tuesday after an experimental blood cancer therapy disappointed investors. That may spell more bad news for a Cathie Wood fund ...</p>\n\n<a href=\"https://finance.yahoo.com/news/cathie-wood-ark-funds-snapped-230102086.html\">网页链接</a>\n\n</div>\n","source":"lsy1612507957220","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood’s ARK Funds Snapped Up Crispr Shares Ahead of Plunge</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood’s ARK Funds Snapped Up Crispr Shares Ahead of Plunge\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-13 08:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/cathie-wood-ark-funds-snapped-230102086.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Bloomberg) -- Crispr Therapeutics AG plunged 8.8% in postmarket trading Tuesday after an experimental blood cancer therapy disappointed investors. That may spell more bad news for a Cathie Wood fund ...</p>\n\n<a href=\"https://finance.yahoo.com/news/cathie-wood-ark-funds-snapped-230102086.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRSP","symbol_name":"CRISPR Therapeutics AG","start_time":0,"source_url":"https://finance.yahoo.com/news/cathie-wood-ark-funds-snapped-230102086.html","article_id":"1113160181","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1113160181","pubTimestamp":1634084984,"columns":[],"sourceInfo":{"source_id":"lsy1612507957220","name":"finance.yahoo"},"weMediaInfo":null,"summary":"(Bloomberg) -- Crispr Therapeutics AG plunged 8.8% in postmarket trading Tuesday after an experiment","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"CRSP":"CRISPR Therapeutics AG"},"translate_title":"凯茜·伍德的方舟基金在Crispr股价暴跌前抢购了该股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRSP":0.9},"content_text":"(Bloomberg) -- Crispr Therapeutics AG plunged 8.8% in postmarket trading Tuesday after an experimental blood cancer therapy disappointed investors. That may spell more bad news for a Cathie Wood fund that’s already slid more than 20% this year.\nFunds at Cathie Wood’s Ark Investment Management snatched up shares of the biotech company and another gene-editing peer Intellia Therapeutics Inc. ahead of Crispr’s results. ARK Investment Management is a top holder in Crispr, Intellia and Editas Medicine Inc., all of which use gene-editing technology known as Crispr.\nCrispr fell after its CAR-T cell therapy cleared cancer cells in nine patients out of 24. Investors were hoping the so-called “off the shelf” treatment made from healthy donor cells would work better than existing therapies.\nIn the days leading up to the results the ARK Genomic Revolution ETF, or ARKG, and Wood’s flagship fund, the ARK Innovation (ARKK) added to positions in Crisp and Intellia. While Intellia rallied after positive results with partner and Regeneron Pharmaceuticals Inc., other stocks in the gene-editing sector have performed poorly this year as safety concerns and other setbacks hampered sentiment.\nThe ARK Genomic Revolution has peeled off 22% so far this year while ARKK has dropped 10%.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[{"id":822814116,"gmtCreate":1634113464046,"gmtModify":1634113464134,"author":{"id":"3576575729067569","authorId":"3576575729067569","name":"Ares_M","avatar":"https://static.tigerbbs.com/491b8c393aef71494a2e01a221f50bbc","vip":1,"crmLevel":12,"crmLevelSwitch":0,"idStr":"3576575729067569","authorIdStr":"3576575729067569"},"htmlText":"Anybody with some knowledge in Genetic engineering would take this as a chance to buy the dip, CRSP is only going one way on the long term: up","listText":"Anybody with some knowledge in Genetic engineering would take this as a chance to buy the dip, CRSP is only going one way on the long term: up","text":"Anybody with some knowledge in Genetic engineering would take this as a chance to buy the dip, CRSP is only going one way on the long term: up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/822814116","repostId":1113160181,"repostType":2,"repost":{"id":"1113160181","kind":"news","pubTimestamp":1634084984,"share":"https://www.laohu8.com/m/news/1113160181?lang=zh_CN&edition=full","pubTime":"2021-10-13 08:29","market":"us","language":"en","title":"Cathie Wood’s ARK Funds Snapped Up Crispr Shares Ahead of Plunge<blockquote>Cathie Wood的ARK基金在暴跌前抢购了Crispr股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1113160181","media":"Bloomberg","summary":"(Bloomberg) -- Crispr Therapeutics AG plunged 8.8% in postmarket trading Tuesday after an experiment","content":"<p>(Bloomberg) -- Crispr Therapeutics AG plunged 8.8% in postmarket trading Tuesday after an experimental blood cancer therapy disappointed investors. That may spell more bad news for a Cathie Wood fund that’s already slid more than 20% this year.</p><p><blockquote>（彭博社）——Crispr Therapeutics AG周二在盘后交易中暴跌8.8%，此前一种实验性血癌疗法令投资者失望。对于今年已下跌超过20%的Cathie Wood基金来说，这可能意味着更多坏消息。</blockquote></p><p> Funds at Cathie Wood’s Ark Investment Management snatched up shares of the biotech company and another gene-editing peer Intellia Therapeutics Inc. ahead of Crispr’s results. ARK Investment Management is a top holder in Crispr, Intellia and Editas Medicine Inc., all of which use gene-editing technology known as Crispr.</p><p><blockquote>Cathie Wood的Ark Investment Management的基金在Crispr公布结果之前抢购了这家生物技术公司和另一家基因编辑同行Intellia Therapeutics Inc.的股票。方舟投资管理公司是Crispr、Intellia和Editas Medicine Inc.的最大持有者，所有这些公司都使用被称为Crispr的基因编辑技术。</blockquote></p><p> Crispr fell after its CAR-T cell therapy cleared cancer cells in nine patients out of 24. Investors were hoping the so-called “off the shelf” treatment made from healthy donor cells would work better than existing therapies.</p><p><blockquote>Crispr在其CAR-T细胞疗法清除了24名患者中9名患者的癌细胞后股价下跌。投资者希望由健康供体细胞制成的所谓“现成”疗法能够比现有疗法效果更好。</blockquote></p><p> In the days leading up to the results the ARK Genomic Revolution ETF, or ARKG, and Wood’s flagship fund, the ARK Innovation (ARKK) added to positions in Crisp and Intellia. While Intellia rallied after positive results with partner and Regeneron Pharmaceuticals Inc., other stocks in the gene-editing sector have performed poorly this year as safety concerns and other setbacks hampered sentiment.</p><p><blockquote>在结果公布前的几天里，ARK Genomic Revolution ETF（ARKG）和Wood的旗舰基金ARK Innovation（ARKK）增持了Crisp和Intellia的头寸。虽然Intellia在与partner和再生元制药公司取得积极成果后上涨，但由于安全担忧和其他挫折阻碍了市场情绪，基因编辑行业的其他股票今年表现不佳。</blockquote></p><p> The ARK Genomic Revolution has peeled off 22% so far this year while ARKK has dropped 10%.</p><p><blockquote>今年迄今为止，ARK基因组革命已下跌22%，而ARKK则下跌10%。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood’s ARK Funds Snapped Up Crispr Shares Ahead of Plunge<blockquote>Cathie Wood的ARK基金在暴跌前抢购了Crispr股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood’s ARK Funds Snapped Up Crispr Shares Ahead of Plunge<blockquote>Cathie Wood的ARK基金在暴跌前抢购了Crispr股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Bloomberg</strong><span class=\"h-time small\">2021-10-13 08:29</span>\n</p>\n</h4>\n</header>\n<article>\n<p>(Bloomberg) -- Crispr Therapeutics AG plunged 8.8% in postmarket trading Tuesday after an experimental blood cancer therapy disappointed investors. That may spell more bad news for a Cathie Wood fund that’s already slid more than 20% this year.</p><p><blockquote>（彭博社）——Crispr Therapeutics AG周二在盘后交易中暴跌8.8%，此前一种实验性血癌疗法令投资者失望。对于今年已下跌超过20%的Cathie Wood基金来说，这可能意味着更多坏消息。</blockquote></p><p> Funds at Cathie Wood’s Ark Investment Management snatched up shares of the biotech company and another gene-editing peer Intellia Therapeutics Inc. ahead of Crispr’s results. ARK Investment Management is a top holder in Crispr, Intellia and Editas Medicine Inc., all of which use gene-editing technology known as Crispr.</p><p><blockquote>Cathie Wood的Ark Investment Management的基金在Crispr公布结果之前抢购了这家生物技术公司和另一家基因编辑同行Intellia Therapeutics Inc.的股票。方舟投资管理公司是Crispr、Intellia和Editas Medicine Inc.的最大持有者，所有这些公司都使用被称为Crispr的基因编辑技术。</blockquote></p><p> Crispr fell after its CAR-T cell therapy cleared cancer cells in nine patients out of 24. Investors were hoping the so-called “off the shelf” treatment made from healthy donor cells would work better than existing therapies.</p><p><blockquote>Crispr在其CAR-T细胞疗法清除了24名患者中9名患者的癌细胞后股价下跌。投资者希望由健康供体细胞制成的所谓“现成”疗法能够比现有疗法效果更好。</blockquote></p><p> In the days leading up to the results the ARK Genomic Revolution ETF, or ARKG, and Wood’s flagship fund, the ARK Innovation (ARKK) added to positions in Crisp and Intellia. While Intellia rallied after positive results with partner and Regeneron Pharmaceuticals Inc., other stocks in the gene-editing sector have performed poorly this year as safety concerns and other setbacks hampered sentiment.</p><p><blockquote>在结果公布前的几天里，ARK Genomic Revolution ETF（ARKG）和Wood的旗舰基金ARK Innovation（ARKK）增持了Crisp和Intellia的头寸。虽然Intellia在与partner和再生元制药公司取得积极成果后上涨，但由于安全担忧和其他挫折阻碍了市场情绪，基因编辑行业的其他股票今年表现不佳。</blockquote></p><p> The ARK Genomic Revolution has peeled off 22% so far this year while ARKK has dropped 10%.</p><p><blockquote>今年迄今为止，ARK基因组革命已下跌22%，而ARKK则下跌10%。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/cathie-wood-ark-funds-snapped-230102086.html\">Bloomberg</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CRSP":"CRISPR Therapeutics AG"},"source_url":"https://finance.yahoo.com/news/cathie-wood-ark-funds-snapped-230102086.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1113160181","content_text":"(Bloomberg) -- Crispr Therapeutics AG plunged 8.8% in postmarket trading Tuesday after an experimental blood cancer therapy disappointed investors. That may spell more bad news for a Cathie Wood fund that’s already slid more than 20% this year.\nFunds at Cathie Wood’s Ark Investment Management snatched up shares of the biotech company and another gene-editing peer Intellia Therapeutics Inc. ahead of Crispr’s results. ARK Investment Management is a top holder in Crispr, Intellia and Editas Medicine Inc., all of which use gene-editing technology known as Crispr.\nCrispr fell after its CAR-T cell therapy cleared cancer cells in nine patients out of 24. Investors were hoping the so-called “off the shelf” treatment made from healthy donor cells would work better than existing therapies.\nIn the days leading up to the results the ARK Genomic Revolution ETF, or ARKG, and Wood’s flagship fund, the ARK Innovation (ARKK) added to positions in Crisp and Intellia. While Intellia rallied after positive results with partner and Regeneron Pharmaceuticals Inc., other stocks in the gene-editing sector have performed poorly this year as safety concerns and other setbacks hampered sentiment.\nThe ARK Genomic Revolution has peeled off 22% so far this year while ARKK has dropped 10%.","news_type":1,"symbols_score_info":{"CRSP":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":822950298,"gmtCreate":1634086761446,"gmtModify":1634086762472,"author":{"id":"3572914809308233","authorId":"3572914809308233","name":"raidou","avatar":"https://static.tigerbbs.com/d897c7c5c5ab650d7cee80180e68677f","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3572914809308233","authorIdStr":"3572914809308233"},"htmlText":"Woooo","listText":"Woooo","text":"Woooo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":13,"repostSize":0,"link":"https://laohu8.com/post/822950298","repostId":1113160181,"repostType":4,"repost":{"id":"1113160181","kind":"news","pubTimestamp":1634084984,"share":"https://www.laohu8.com/m/news/1113160181?lang=zh_CN&edition=full","pubTime":"2021-10-13 08:29","market":"us","language":"en","title":"Cathie Wood’s ARK Funds Snapped Up Crispr Shares Ahead of Plunge<blockquote>Cathie Wood的ARK基金在暴跌前抢购了Crispr股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1113160181","media":"Bloomberg","summary":"(Bloomberg) -- Crispr Therapeutics AG plunged 8.8% in postmarket trading Tuesday after an experiment","content":"<p>(Bloomberg) -- Crispr Therapeutics AG plunged 8.8% in postmarket trading Tuesday after an experimental blood cancer therapy disappointed investors. That may spell more bad news for a Cathie Wood fund that’s already slid more than 20% this year.</p><p><blockquote>（彭博社）——Crispr Therapeutics AG周二在盘后交易中暴跌8.8%，此前一种实验性血癌疗法令投资者失望。对于今年已下跌超过20%的Cathie Wood基金来说，这可能意味着更多坏消息。</blockquote></p><p> Funds at Cathie Wood’s Ark Investment Management snatched up shares of the biotech company and another gene-editing peer Intellia Therapeutics Inc. ahead of Crispr’s results. ARK Investment Management is a top holder in Crispr, Intellia and Editas Medicine Inc., all of which use gene-editing technology known as Crispr.</p><p><blockquote>Cathie Wood的Ark Investment Management的基金在Crispr公布结果之前抢购了这家生物技术公司和另一家基因编辑同行Intellia Therapeutics Inc.的股票。方舟投资管理公司是Crispr、Intellia和Editas Medicine Inc.的最大持有者，所有这些公司都使用被称为Crispr的基因编辑技术。</blockquote></p><p> Crispr fell after its CAR-T cell therapy cleared cancer cells in nine patients out of 24. Investors were hoping the so-called “off the shelf” treatment made from healthy donor cells would work better than existing therapies.</p><p><blockquote>Crispr在其CAR-T细胞疗法清除了24名患者中9名患者的癌细胞后股价下跌。投资者希望由健康供体细胞制成的所谓“现成”疗法能够比现有疗法效果更好。</blockquote></p><p> In the days leading up to the results the ARK Genomic Revolution ETF, or ARKG, and Wood’s flagship fund, the ARK Innovation (ARKK) added to positions in Crisp and Intellia. While Intellia rallied after positive results with partner and Regeneron Pharmaceuticals Inc., other stocks in the gene-editing sector have performed poorly this year as safety concerns and other setbacks hampered sentiment.</p><p><blockquote>在结果公布前的几天里，ARK Genomic Revolution ETF（ARKG）和Wood的旗舰基金ARK Innovation（ARKK）增持了Crisp和Intellia的头寸。虽然Intellia在与partner和再生元制药公司取得积极成果后上涨，但由于安全担忧和其他挫折阻碍了市场情绪，基因编辑行业的其他股票今年表现不佳。</blockquote></p><p> The ARK Genomic Revolution has peeled off 22% so far this year while ARKK has dropped 10%.</p><p><blockquote>今年迄今为止，ARK基因组革命已下跌22%，而ARKK则下跌10%。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood’s ARK Funds Snapped Up Crispr Shares Ahead of Plunge<blockquote>Cathie Wood的ARK基金在暴跌前抢购了Crispr股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood’s ARK Funds Snapped Up Crispr Shares Ahead of Plunge<blockquote>Cathie Wood的ARK基金在暴跌前抢购了Crispr股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Bloomberg</strong><span class=\"h-time small\">2021-10-13 08:29</span>\n</p>\n</h4>\n</header>\n<article>\n<p>(Bloomberg) -- Crispr Therapeutics AG plunged 8.8% in postmarket trading Tuesday after an experimental blood cancer therapy disappointed investors. That may spell more bad news for a Cathie Wood fund that’s already slid more than 20% this year.</p><p><blockquote>（彭博社）——Crispr Therapeutics AG周二在盘后交易中暴跌8.8%，此前一种实验性血癌疗法令投资者失望。对于今年已下跌超过20%的Cathie Wood基金来说，这可能意味着更多坏消息。</blockquote></p><p> Funds at Cathie Wood’s Ark Investment Management snatched up shares of the biotech company and another gene-editing peer Intellia Therapeutics Inc. ahead of Crispr’s results. ARK Investment Management is a top holder in Crispr, Intellia and Editas Medicine Inc., all of which use gene-editing technology known as Crispr.</p><p><blockquote>Cathie Wood的Ark Investment Management的基金在Crispr公布结果之前抢购了这家生物技术公司和另一家基因编辑同行Intellia Therapeutics Inc.的股票。方舟投资管理公司是Crispr、Intellia和Editas Medicine Inc.的最大持有者，所有这些公司都使用被称为Crispr的基因编辑技术。</blockquote></p><p> Crispr fell after its CAR-T cell therapy cleared cancer cells in nine patients out of 24. Investors were hoping the so-called “off the shelf” treatment made from healthy donor cells would work better than existing therapies.</p><p><blockquote>Crispr在其CAR-T细胞疗法清除了24名患者中9名患者的癌细胞后股价下跌。投资者希望由健康供体细胞制成的所谓“现成”疗法能够比现有疗法效果更好。</blockquote></p><p> In the days leading up to the results the ARK Genomic Revolution ETF, or ARKG, and Wood’s flagship fund, the ARK Innovation (ARKK) added to positions in Crisp and Intellia. While Intellia rallied after positive results with partner and Regeneron Pharmaceuticals Inc., other stocks in the gene-editing sector have performed poorly this year as safety concerns and other setbacks hampered sentiment.</p><p><blockquote>在结果公布前的几天里，ARK Genomic Revolution ETF（ARKG）和Wood的旗舰基金ARK Innovation（ARKK）增持了Crisp和Intellia的头寸。虽然Intellia在与partner和再生元制药公司取得积极成果后上涨，但由于安全担忧和其他挫折阻碍了市场情绪，基因编辑行业的其他股票今年表现不佳。</blockquote></p><p> The ARK Genomic Revolution has peeled off 22% so far this year while ARKK has dropped 10%.</p><p><blockquote>今年迄今为止，ARK基因组革命已下跌22%，而ARKK则下跌10%。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/cathie-wood-ark-funds-snapped-230102086.html\">Bloomberg</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CRSP":"CRISPR Therapeutics AG"},"source_url":"https://finance.yahoo.com/news/cathie-wood-ark-funds-snapped-230102086.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1113160181","content_text":"(Bloomberg) -- Crispr Therapeutics AG plunged 8.8% in postmarket trading Tuesday after an experimental blood cancer therapy disappointed investors. That may spell more bad news for a Cathie Wood fund that’s already slid more than 20% this year.\nFunds at Cathie Wood’s Ark Investment Management snatched up shares of the biotech company and another gene-editing peer Intellia Therapeutics Inc. ahead of Crispr’s results. ARK Investment Management is a top holder in Crispr, Intellia and Editas Medicine Inc., all of which use gene-editing technology known as Crispr.\nCrispr fell after its CAR-T cell therapy cleared cancer cells in nine patients out of 24. Investors were hoping the so-called “off the shelf” treatment made from healthy donor cells would work better than existing therapies.\nIn the days leading up to the results the ARK Genomic Revolution ETF, or ARKG, and Wood’s flagship fund, the ARK Innovation (ARKK) added to positions in Crisp and Intellia. While Intellia rallied after positive results with partner and Regeneron Pharmaceuticals Inc., other stocks in the gene-editing sector have performed poorly this year as safety concerns and other setbacks hampered sentiment.\nThe ARK Genomic Revolution has peeled off 22% so far this year while ARKK has dropped 10%.","news_type":1,"symbols_score_info":{"CRSP":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6179918,"gmtCreate":1634086780029,"gmtModify":1634637234992,"authorId":3572914809308233,"author":{"id":3572914809308233,"idStr":"3572914809308233","authorId":3572914809308233,"name":"raidou","avatar":"https://static.tigerbbs.com/d897c7c5c5ab650d7cee80180e68677f","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":822950298,"type":1,"supId":0,"prevId":0,"content":"[龇牙] [微笑] [龇牙] [惊讶] [微笑] [惊讶] [笑哭] [惊讶] [笑哭] [惊讶] [笑哭] [惊讶] [惊讶] [笑哭] [生气] [微笑] [生气] [微笑] [生气] [微笑] [生气] [生气] [微笑]","text":"[龇牙] [微笑] [龇牙] [惊讶] [微笑] [惊讶] [笑哭] [惊讶] [笑哭] [惊讶] [笑哭] [惊讶] [惊讶] [笑哭] [生气] [微笑] [生气] [微笑] [生气] [微笑] [生气] [生气] [微笑]","html":"[龇牙] [微笑] [龇牙] [惊讶] [微笑] [惊讶] [笑哭] [惊讶] [笑哭] [惊讶] [笑哭] [惊讶] [惊讶] [笑哭] [生气] [微笑] [生气] [微笑] [生气] [微笑] [生气] [生气] [微笑]"},{"id":6179921,"gmtCreate":1634086786613,"gmtModify":1634637234774,"authorId":3572914809308233,"author":{"id":3572914809308233,"idStr":"3572914809308233","authorId":3572914809308233,"name":"raidou","avatar":"https://static.tigerbbs.com/d897c7c5c5ab650d7cee80180e68677f","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":822950298,"type":1,"supId":0,"prevId":0,"content":"[龇牙] [微笑] [龇牙] [微笑] [惊讶] [开心] [惊讶] [惊讶] [开心] [惊讶] [开心] [惊讶] [开心] [惊讶] [难过] [惊讶] [难过] [惊讶] [惊讶] [难过] [惊讶] [开心] [害羞] [开心] [开心]","text":"[龇牙] [微笑] [龇牙] [微笑] [惊讶] [开心] [惊讶] [惊讶] [开心] [惊讶] [开心] [惊讶] [开心] [惊讶] [难过] [惊讶] [难过] [惊讶] [惊讶] [难过] [惊讶] [开心] [害羞] [开心] [开心]","html":"[龇牙] [微笑] [龇牙] [微笑] [惊讶] [开心] [惊讶] [惊讶] [开心] [惊讶] [开心] [惊讶] [开心] [惊讶] [难过] [惊讶] [难过] [惊讶] [惊讶] [难过] [惊讶] [开心] [害羞] [开心] [开心]"},{"id":6179924,"gmtCreate":1634086792828,"gmtModify":1634637234449,"authorId":3572914809308233,"author":{"id":3572914809308233,"idStr":"3572914809308233","authorId":3572914809308233,"name":"raidou","avatar":"https://static.tigerbbs.com/d897c7c5c5ab650d7cee80180e68677f","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":822950298,"type":1,"supId":0,"prevId":0,"content":"[流泪] [笑哭] [害羞] [笑哭] [害羞] [笑哭] [害羞] [害羞] [笑哭] [害羞] [笑哭] [害羞] [笑哭] [害羞] [笑哭] [害羞] [笑哭] [真香] [笑哭] [笑哭]","text":"[流泪] [笑哭] [害羞] [笑哭] [害羞] [笑哭] [害羞] [害羞] [笑哭] [害羞] [笑哭] [害羞] [笑哭] [害羞] [笑哭] [害羞] [笑哭] [真香] [笑哭] [笑哭]","html":"[流泪] [笑哭] [害羞] [笑哭] [害羞] [笑哭] [害羞] [害羞] [笑哭] [害羞] [笑哭] [害羞] [笑哭] [害羞] [笑哭] [害羞] [笑哭] [真香] [笑哭] [笑哭]"},{"id":6179926,"gmtCreate":1634086803333,"gmtModify":1634637234233,"authorId":3572914809308233,"author":{"id":3572914809308233,"idStr":"3572914809308233","authorId":3572914809308233,"name":"raidou","avatar":"https://static.tigerbbs.com/d897c7c5c5ab650d7cee80180e68677f","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":822950298,"type":1,"supId":0,"prevId":0,"content":"[龇牙] [笑哭] [龇牙] [笑哭] [龇牙] [鬼脸] [难过] [鬼脸] [无语] [鬼脸] [无语] [龇牙] [无语] [龇牙] [无语] [龇牙] [无语] [龇牙] [无语] [龇牙] [龇牙] [无语]","text":"[龇牙] [笑哭] [龇牙] [笑哭] [龇牙] [鬼脸] [难过] [鬼脸] [无语] [鬼脸] [无语] [龇牙] [无语] [龇牙] [无语] [龇牙] [无语] [龇牙] [无语] [龇牙] [龇牙] [无语]","html":"[龇牙] [笑哭] [龇牙] [笑哭] [龇牙] [鬼脸] [难过] [鬼脸] [无语] [鬼脸] [无语] [龇牙] [无语] [龇牙] [无语] [龇牙] [无语] [龇牙] [无语] [龇牙] [龇牙] [无语]"},{"id":6179929,"gmtCreate":1634086808704,"gmtModify":1634637234016,"authorId":3572914809308233,"author":{"id":3572914809308233,"idStr":"3572914809308233","authorId":3572914809308233,"name":"raidou","avatar":"https://static.tigerbbs.com/d897c7c5c5ab650d7cee80180e68677f","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":822950298,"type":1,"supId":6179918,"prevId":0,"content":"[龇牙] [微笑] [龇牙] [微笑] [龇牙] [微笑] [惊讶] [惊讶] [微笑] [惊讶] [微笑] [惊讶] [微笑] [惊讶] [微笑] [惊讶] [微笑] [惊讶] [开心] [开心]","text":"[龇牙] [微笑] [龇牙] [微笑] [龇牙] [微笑] [惊讶] [惊讶] [微笑] [惊讶] [微笑] [惊讶] [微笑] [惊讶] [微笑] [惊讶] [微笑] [惊讶] [开心] [开心]","html":"[龇牙] [微笑] [龇牙] [微笑] [龇牙] [微笑] [惊讶] [惊讶] [微笑] [惊讶] [微笑] [惊讶] [微笑] [惊讶] [微笑] [惊讶] [微笑] [惊讶] [开心] [开心]"}],"langContent":"CN"},{"id":822927796,"gmtCreate":1634086733745,"gmtModify":1634086734341,"author":{"id":"3567411499210880","authorId":"3567411499210880","name":"Nebhol","avatar":"https://static.tigerbbs.com/b0bfc2a45b91e41a283614268857b3a5","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3567411499210880","authorIdStr":"3567411499210880"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/822927796","repostId":1113160181,"repostType":4,"repost":{"id":"1113160181","kind":"news","pubTimestamp":1634084984,"share":"https://www.laohu8.com/m/news/1113160181?lang=zh_CN&edition=full","pubTime":"2021-10-13 08:29","market":"us","language":"en","title":"Cathie Wood’s ARK Funds Snapped Up Crispr Shares Ahead of Plunge<blockquote>Cathie Wood的ARK基金在暴跌前抢购了Crispr股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1113160181","media":"Bloomberg","summary":"(Bloomberg) -- Crispr Therapeutics AG plunged 8.8% in postmarket trading Tuesday after an experiment","content":"<p>(Bloomberg) -- Crispr Therapeutics AG plunged 8.8% in postmarket trading Tuesday after an experimental blood cancer therapy disappointed investors. That may spell more bad news for a Cathie Wood fund that’s already slid more than 20% this year.</p><p><blockquote>（彭博社）——Crispr Therapeutics AG周二在盘后交易中暴跌8.8%，此前一种实验性血癌疗法令投资者失望。对于今年已下跌超过20%的Cathie Wood基金来说，这可能意味着更多坏消息。</blockquote></p><p> Funds at Cathie Wood’s Ark Investment Management snatched up shares of the biotech company and another gene-editing peer Intellia Therapeutics Inc. ahead of Crispr’s results. ARK Investment Management is a top holder in Crispr, Intellia and Editas Medicine Inc., all of which use gene-editing technology known as Crispr.</p><p><blockquote>Cathie Wood的Ark Investment Management的基金在Crispr公布结果之前抢购了这家生物技术公司和另一家基因编辑同行Intellia Therapeutics Inc.的股票。方舟投资管理公司是Crispr、Intellia和Editas Medicine Inc.的最大持有者，所有这些公司都使用被称为Crispr的基因编辑技术。</blockquote></p><p> Crispr fell after its CAR-T cell therapy cleared cancer cells in nine patients out of 24. Investors were hoping the so-called “off the shelf” treatment made from healthy donor cells would work better than existing therapies.</p><p><blockquote>Crispr在其CAR-T细胞疗法清除了24名患者中9名患者的癌细胞后股价下跌。投资者希望由健康供体细胞制成的所谓“现成”疗法能够比现有疗法效果更好。</blockquote></p><p> In the days leading up to the results the ARK Genomic Revolution ETF, or ARKG, and Wood’s flagship fund, the ARK Innovation (ARKK) added to positions in Crisp and Intellia. While Intellia rallied after positive results with partner and Regeneron Pharmaceuticals Inc., other stocks in the gene-editing sector have performed poorly this year as safety concerns and other setbacks hampered sentiment.</p><p><blockquote>在结果公布前的几天里，ARK Genomic Revolution ETF（ARKG）和Wood的旗舰基金ARK Innovation（ARKK）增持了Crisp和Intellia的头寸。虽然Intellia在与partner和再生元制药公司取得积极成果后上涨，但由于安全担忧和其他挫折阻碍了市场情绪，基因编辑行业的其他股票今年表现不佳。</blockquote></p><p> The ARK Genomic Revolution has peeled off 22% so far this year while ARKK has dropped 10%.</p><p><blockquote>今年迄今为止，ARK基因组革命已下跌22%，而ARKK则下跌10%。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood’s ARK Funds Snapped Up Crispr Shares Ahead of Plunge<blockquote>Cathie Wood的ARK基金在暴跌前抢购了Crispr股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood’s ARK Funds Snapped Up Crispr Shares Ahead of Plunge<blockquote>Cathie Wood的ARK基金在暴跌前抢购了Crispr股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Bloomberg</strong><span class=\"h-time small\">2021-10-13 08:29</span>\n</p>\n</h4>\n</header>\n<article>\n<p>(Bloomberg) -- Crispr Therapeutics AG plunged 8.8% in postmarket trading Tuesday after an experimental blood cancer therapy disappointed investors. That may spell more bad news for a Cathie Wood fund that’s already slid more than 20% this year.</p><p><blockquote>（彭博社）——Crispr Therapeutics AG周二在盘后交易中暴跌8.8%，此前一种实验性血癌疗法令投资者失望。对于今年已下跌超过20%的Cathie Wood基金来说，这可能意味着更多坏消息。</blockquote></p><p> Funds at Cathie Wood’s Ark Investment Management snatched up shares of the biotech company and another gene-editing peer Intellia Therapeutics Inc. ahead of Crispr’s results. ARK Investment Management is a top holder in Crispr, Intellia and Editas Medicine Inc., all of which use gene-editing technology known as Crispr.</p><p><blockquote>Cathie Wood的Ark Investment Management的基金在Crispr公布结果之前抢购了这家生物技术公司和另一家基因编辑同行Intellia Therapeutics Inc.的股票。方舟投资管理公司是Crispr、Intellia和Editas Medicine Inc.的最大持有者，所有这些公司都使用被称为Crispr的基因编辑技术。</blockquote></p><p> Crispr fell after its CAR-T cell therapy cleared cancer cells in nine patients out of 24. Investors were hoping the so-called “off the shelf” treatment made from healthy donor cells would work better than existing therapies.</p><p><blockquote>Crispr在其CAR-T细胞疗法清除了24名患者中9名患者的癌细胞后股价下跌。投资者希望由健康供体细胞制成的所谓“现成”疗法能够比现有疗法效果更好。</blockquote></p><p> In the days leading up to the results the ARK Genomic Revolution ETF, or ARKG, and Wood’s flagship fund, the ARK Innovation (ARKK) added to positions in Crisp and Intellia. While Intellia rallied after positive results with partner and Regeneron Pharmaceuticals Inc., other stocks in the gene-editing sector have performed poorly this year as safety concerns and other setbacks hampered sentiment.</p><p><blockquote>在结果公布前的几天里，ARK Genomic Revolution ETF（ARKG）和Wood的旗舰基金ARK Innovation（ARKK）增持了Crisp和Intellia的头寸。虽然Intellia在与partner和再生元制药公司取得积极成果后上涨，但由于安全担忧和其他挫折阻碍了市场情绪，基因编辑行业的其他股票今年表现不佳。</blockquote></p><p> The ARK Genomic Revolution has peeled off 22% so far this year while ARKK has dropped 10%.</p><p><blockquote>今年迄今为止，ARK基因组革命已下跌22%，而ARKK则下跌10%。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/cathie-wood-ark-funds-snapped-230102086.html\">Bloomberg</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CRSP":"CRISPR Therapeutics AG"},"source_url":"https://finance.yahoo.com/news/cathie-wood-ark-funds-snapped-230102086.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1113160181","content_text":"(Bloomberg) -- Crispr Therapeutics AG plunged 8.8% in postmarket trading Tuesday after an experimental blood cancer therapy disappointed investors. That may spell more bad news for a Cathie Wood fund that’s already slid more than 20% this year.\nFunds at Cathie Wood’s Ark Investment Management snatched up shares of the biotech company and another gene-editing peer Intellia Therapeutics Inc. ahead of Crispr’s results. ARK Investment Management is a top holder in Crispr, Intellia and Editas Medicine Inc., all of which use gene-editing technology known as Crispr.\nCrispr fell after its CAR-T cell therapy cleared cancer cells in nine patients out of 24. Investors were hoping the so-called “off the shelf” treatment made from healthy donor cells would work better than existing therapies.\nIn the days leading up to the results the ARK Genomic Revolution ETF, or ARKG, and Wood’s flagship fund, the ARK Innovation (ARKK) added to positions in Crisp and Intellia. While Intellia rallied after positive results with partner and Regeneron Pharmaceuticals Inc., other stocks in the gene-editing sector have performed poorly this year as safety concerns and other setbacks hampered sentiment.\nThe ARK Genomic Revolution has peeled off 22% so far this year while ARKK has dropped 10%.","news_type":1,"symbols_score_info":{"CRSP":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":822961786,"gmtCreate":1634085576698,"gmtModify":1634085576914,"author":{"id":"3581581151725380","authorId":"3581581151725380","name":"HermioneG","avatar":"https://static.tigerbbs.com/449ae31dcb8cfcd4dcedab9bc5dec8aa","vip":1,"crmLevel":11,"crmLevelSwitch":0,"idStr":"3581581151725380","authorIdStr":"3581581151725380"},"htmlText":"Awesome!","listText":"Awesome!","text":"Awesome!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/822961786","repostId":1113160181,"repostType":4,"repost":{"id":"1113160181","kind":"news","pubTimestamp":1634084984,"share":"https://www.laohu8.com/m/news/1113160181?lang=zh_CN&edition=full","pubTime":"2021-10-13 08:29","market":"us","language":"en","title":"Cathie Wood’s ARK Funds Snapped Up Crispr Shares Ahead of Plunge<blockquote>Cathie Wood的ARK基金在暴跌前抢购了Crispr股票</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1113160181","media":"Bloomberg","summary":"(Bloomberg) -- Crispr Therapeutics AG plunged 8.8% in postmarket trading Tuesday after an experiment","content":"<p>(Bloomberg) -- Crispr Therapeutics AG plunged 8.8% in postmarket trading Tuesday after an experimental blood cancer therapy disappointed investors. That may spell more bad news for a Cathie Wood fund that’s already slid more than 20% this year.</p><p><blockquote>（彭博社）——Crispr Therapeutics AG周二在盘后交易中暴跌8.8%，此前一种实验性血癌疗法令投资者失望。对于今年已下跌超过20%的Cathie Wood基金来说，这可能意味着更多坏消息。</blockquote></p><p> Funds at Cathie Wood’s Ark Investment Management snatched up shares of the biotech company and another gene-editing peer Intellia Therapeutics Inc. ahead of Crispr’s results. ARK Investment Management is a top holder in Crispr, Intellia and Editas Medicine Inc., all of which use gene-editing technology known as Crispr.</p><p><blockquote>Cathie Wood的Ark Investment Management的基金在Crispr公布结果之前抢购了这家生物技术公司和另一家基因编辑同行Intellia Therapeutics Inc.的股票。方舟投资管理公司是Crispr、Intellia和Editas Medicine Inc.的最大持有者，所有这些公司都使用被称为Crispr的基因编辑技术。</blockquote></p><p> Crispr fell after its CAR-T cell therapy cleared cancer cells in nine patients out of 24. Investors were hoping the so-called “off the shelf” treatment made from healthy donor cells would work better than existing therapies.</p><p><blockquote>Crispr在其CAR-T细胞疗法清除了24名患者中9名患者的癌细胞后股价下跌。投资者希望由健康供体细胞制成的所谓“现成”疗法能够比现有疗法效果更好。</blockquote></p><p> In the days leading up to the results the ARK Genomic Revolution ETF, or ARKG, and Wood’s flagship fund, the ARK Innovation (ARKK) added to positions in Crisp and Intellia. While Intellia rallied after positive results with partner and Regeneron Pharmaceuticals Inc., other stocks in the gene-editing sector have performed poorly this year as safety concerns and other setbacks hampered sentiment.</p><p><blockquote>在结果公布前的几天里，ARK Genomic Revolution ETF（ARKG）和Wood的旗舰基金ARK Innovation（ARKK）增持了Crisp和Intellia的头寸。虽然Intellia在与partner和再生元制药公司取得积极成果后上涨，但由于安全担忧和其他挫折阻碍了市场情绪，基因编辑行业的其他股票今年表现不佳。</blockquote></p><p> The ARK Genomic Revolution has peeled off 22% so far this year while ARKK has dropped 10%.</p><p><blockquote>今年迄今为止，ARK基因组革命已下跌22%，而ARKK则下跌10%。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood’s ARK Funds Snapped Up Crispr Shares Ahead of Plunge<blockquote>Cathie Wood的ARK基金在暴跌前抢购了Crispr股票</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood’s ARK Funds Snapped Up Crispr Shares Ahead of Plunge<blockquote>Cathie Wood的ARK基金在暴跌前抢购了Crispr股票</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Bloomberg</strong><span class=\"h-time small\">2021-10-13 08:29</span>\n</p>\n</h4>\n</header>\n<article>\n<p>(Bloomberg) -- Crispr Therapeutics AG plunged 8.8% in postmarket trading Tuesday after an experimental blood cancer therapy disappointed investors. That may spell more bad news for a Cathie Wood fund that’s already slid more than 20% this year.</p><p><blockquote>（彭博社）——Crispr Therapeutics AG周二在盘后交易中暴跌8.8%，此前一种实验性血癌疗法令投资者失望。对于今年已下跌超过20%的Cathie Wood基金来说，这可能意味着更多坏消息。</blockquote></p><p> Funds at Cathie Wood’s Ark Investment Management snatched up shares of the biotech company and another gene-editing peer Intellia Therapeutics Inc. ahead of Crispr’s results. ARK Investment Management is a top holder in Crispr, Intellia and Editas Medicine Inc., all of which use gene-editing technology known as Crispr.</p><p><blockquote>Cathie Wood的Ark Investment Management的基金在Crispr公布结果之前抢购了这家生物技术公司和另一家基因编辑同行Intellia Therapeutics Inc.的股票。方舟投资管理公司是Crispr、Intellia和Editas Medicine Inc.的最大持有者，所有这些公司都使用被称为Crispr的基因编辑技术。</blockquote></p><p> Crispr fell after its CAR-T cell therapy cleared cancer cells in nine patients out of 24. Investors were hoping the so-called “off the shelf” treatment made from healthy donor cells would work better than existing therapies.</p><p><blockquote>Crispr在其CAR-T细胞疗法清除了24名患者中9名患者的癌细胞后股价下跌。投资者希望由健康供体细胞制成的所谓“现成”疗法能够比现有疗法效果更好。</blockquote></p><p> In the days leading up to the results the ARK Genomic Revolution ETF, or ARKG, and Wood’s flagship fund, the ARK Innovation (ARKK) added to positions in Crisp and Intellia. While Intellia rallied after positive results with partner and Regeneron Pharmaceuticals Inc., other stocks in the gene-editing sector have performed poorly this year as safety concerns and other setbacks hampered sentiment.</p><p><blockquote>在结果公布前的几天里，ARK Genomic Revolution ETF（ARKG）和Wood的旗舰基金ARK Innovation（ARKK）增持了Crisp和Intellia的头寸。虽然Intellia在与partner和再生元制药公司取得积极成果后上涨，但由于安全担忧和其他挫折阻碍了市场情绪，基因编辑行业的其他股票今年表现不佳。</blockquote></p><p> The ARK Genomic Revolution has peeled off 22% so far this year while ARKK has dropped 10%.</p><p><blockquote>今年迄今为止，ARK基因组革命已下跌22%，而ARKK则下跌10%。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/cathie-wood-ark-funds-snapped-230102086.html\">Bloomberg</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CRSP":"CRISPR Therapeutics AG"},"source_url":"https://finance.yahoo.com/news/cathie-wood-ark-funds-snapped-230102086.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1113160181","content_text":"(Bloomberg) -- Crispr Therapeutics AG plunged 8.8% in postmarket trading Tuesday after an experimental blood cancer therapy disappointed investors. That may spell more bad news for a Cathie Wood fund that’s already slid more than 20% this year.\nFunds at Cathie Wood’s Ark Investment Management snatched up shares of the biotech company and another gene-editing peer Intellia Therapeutics Inc. ahead of Crispr’s results. ARK Investment Management is a top holder in Crispr, Intellia and Editas Medicine Inc., all of which use gene-editing technology known as Crispr.\nCrispr fell after its CAR-T cell therapy cleared cancer cells in nine patients out of 24. Investors were hoping the so-called “off the shelf” treatment made from healthy donor cells would work better than existing therapies.\nIn the days leading up to the results the ARK Genomic Revolution ETF, or ARKG, and Wood’s flagship fund, the ARK Innovation (ARKK) added to positions in Crisp and Intellia. While Intellia rallied after positive results with partner and Regeneron Pharmaceuticals Inc., other stocks in the gene-editing sector have performed poorly this year as safety concerns and other setbacks hampered sentiment.\nThe ARK Genomic Revolution has peeled off 22% so far this year while ARKK has dropped 10%.","news_type":1,"symbols_score_info":{"CRSP":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6179597,"gmtCreate":1634085709337,"gmtModify":1634637263150,"authorId":3575375170329093,"author":{"id":3575375170329093,"idStr":"3575375170329093","authorId":3575375170329093,"name":"Cylee3325","avatar":"https://static.tigerbbs.com/fd1f23984435368a9c89d4e0b0bfff41","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":822961786,"type":1,"supId":0,"prevId":0,"content":"Great ","text":"Great ","html":"Great "},{"id":6180006,"gmtCreate":1634087112119,"gmtModify":1634637227040,"authorId":3574118564601995,"author":{"id":3574118564601995,"idStr":"3574118564601995","authorId":3574118564601995,"name":"RS142","avatar":"https://static.tigerbbs.com/22d2d9b1f352da24e6ea75b557ac987a","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":822961786,"type":1,"supId":0,"prevId":0,"content":"good","text":"good","html":"good"}],"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":56,"commentSize":4,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}